Summary
Eli Lilly and Company's 2008 10-K filing reveals a challenging year marked by significant acquisition-related charges and legal settlements, which resulted in a net loss of $2.07 billion. Despite these headwinds, the company demonstrated resilience with a 9% increase in worldwide sales to $20.38 billion, driven by strong performance in key products like Cymbalta, Cialis, and Alimta. The acquisition of ImClone Systems for $6.5 billion significantly expanded Lilly's oncology portfolio and biotechnology capabilities, albeit with a substantial $4.69 billion charge for acquired in-process research and development. Of critical importance to investors are the substantial charges impacting the bottom line, primarily stemming from the ImClone acquisition and a $1.48 billion charge to resolve investigations into Zyprexa's marketing practices. These items overshadowed otherwise solid operational performance. The company also faces ongoing patent challenges and regulatory scrutiny, particularly concerning Zyprexa and other major products, which could impact future revenues and profitability. However, Lilly maintains a strong financial position with robust operating cash flow and a growing dividend, indicating management's confidence in its future prospects.
Financial Highlights
51 data points| Revenue | $20.37B |
| Cost of Revenue | $4.38B |
| Gross Profit | $16.00B |
| R&D Expenses | $3.84B |
| SG&A Expenses | $6.63B |
| Interest Expense | -$228.30M |
| Net Income | -$2.07B |
| EPS (Basic) | $-1.89 |
| EPS (Diluted) | $-1.89 |
| Shares Outstanding (Basic) | 1.09B |
| Shares Outstanding (Diluted) | 1.09B |
Key Highlights
- 1Worldwide sales grew 9% to $20.38 billion in 2008, driven by strong volume increases in key products.
- 2The company reported a net loss of $2.07 billion in 2008, significantly impacted by a $4.69 billion charge for acquired in-process R&D related to the ImClone acquisition and a $1.48 billion charge for Zyprexa investigation settlements.
- 3Acquisition of ImClone Systems for $6.5 billion bolstered the company's oncology pipeline and biotechnology capabilities.
- 4Key products like Cymbalta, Cialis, and Alimta showed significant sales growth, offsetting declines in other areas.
- 5Eli Lilly is actively defending against patent challenges for several key products, including Cymbalta, Gemzar, Alimta, Evista, and Zyprexa, with potential material adverse impacts if unfavorable outcomes occur.
- 6The company continues to face regulatory scrutiny and legal challenges, particularly related to past marketing and promotional practices, with substantial charges recorded.
- 7Despite the net loss, Eli Lilly demonstrated continued financial strength with strong operating cash flow and maintained its track record of increasing dividends.